Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly

Clinical and Applied Thrombosis/Hemostasis

Volumn 11, Issue 1, 2005, Pages 15-23

  Pineo, Graham F ^a,b   Hull, Russell D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

Author keywords

Bleeding; Deep vein thrombosis; Elderly; Heparin; Low molecular weight heparin; Pulmonary embolism; Renal insufficiency; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; TINZAPARIN; WARFARIN;

AGED; AGING; ANTICOAGULATION; ARTICLE; BLEEDING; BODY WEIGHT; CANCER; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LIVER DISEASE; LONG TERM CARE; LUNG EMBOLISM; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; STATISTICAL SIGNIFICANCE; STEADY STATE; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

AGED; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; OSTEOPOROSIS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 13244287863     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960501100102     Document Type: Article

References (107)

1. Anderson F, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933.
2. Hirsh J. Pulmonary embolism in the elderly. Cardiol Clin 1991;9(3):457.
3. Berman AR. Pulmonary embolism in the elderly. Clin Geriatr Med 2001;17(1):107.
4. Timmons S, Kingston M, Hussain M, Kelly H, Liston R. Pulmonary embolism: Differences in presentation between older and younger patients. Age Ageing 2003;32: 601.
5. Bosson J-L, Labarere J, Sevestre M-A, et al. Deep vein thrombosis in elderly patients hospitalized in subacute care facilities. A multi-center cross-sectional study of risk factors, prophylaxis, and prevalence. Arch Intern Med 2003;163:2613.
6. Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341(11):793.
7. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients. Arch Intern Med 2000;160:3415.
8. McHugh KB, Visani L, DeRosa M, Covezzoli A, Rossi E, Goldhaber SZ. Gender comparisons in pulmonary embolism (Results from the international cooperative pulmonary embolism registry ([ICOPER]). Am J Cardiol 2002;89:616.
9. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon M, Melton III J. Risk factors for deep vein thrombosis and pulmonary embolism. A population-based case-control study. Arch Intern Med 2000;160:809.
10. Geerts WH, Heit JA, Clagett P, et al. Prevention of venous thromboembolism. Chest 2001;119(1):132S.
11. Bergman J-F, Caulin C. Heparin prophylaxis in bedridden patients. Lancet 1996;348:205.
12. Harenberg J, Riess H, Buller HR, Brom J, Weidinger G, Huisman MV. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin. J Hematol 2003;88(10):1157.
13. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomized clinical trials. Thromb Haemost 2000;83:14.
14. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447.
15. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(1):64S.
16. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119 (Suppl. 1):176S.
17. Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment of long-term clinical outcomes of antithrombotic therapy. Arch Intern Med 1997; 157(10):2317.
18. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993;119:874.
19. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(1):108S.
20. Jick H, Slone D, Borda IT, et al. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968; 279:284.
21. Basu D, Gallus AS, Hirsh J, et al. A prospective study of value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324.
22. Levine MN, Hirsh J, Kelton JG. Heparin-induced bleeding. In: Lane D, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications. London, England: Edward Arnold, 1989, pp. 517-532.
23. Campbell NR, Hull RD, Brant R, et al. Aging and heparin-related bleeding. Arch Intern Med 1996;156:857.
24. Yett HS, Skillman JJ, Salzman EW. The hazards of heparin plus aspirin [letter]. N Engl J Med 1978;298:1092.
25. Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 1990;15:15.
26. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956.
27. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336:1689.
28. Boneau B, Buchanan MR, Cade JF, et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985;40:81.
29. Barzu T, Molho P, Tobelem G, et al. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Haematol 1984;26:243.
30. Andriuoli G, Mastacchi R, Barnti M, et al. Comparison of the antithrombotic and hemorrhagic effects of heparin and a new low molecular weight heparin in the rat. Haemostasis 1985;15:324.
31. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 1989;556:245.
32. Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 1982; 59:1239.
33. Kakkar W, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259.
34. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913.
35. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975.
36. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med 1999;130:800.
37. Beyth BJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105: 91.
38. Landefeld CS, McGuire E, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1990;89:569.
39. Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457.
40. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: A multicentre study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993;118:511.
41. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-vein thrombosis. Am J Med 1999;107:414.
42. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348(15):1425.
43. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349(7):631.
44. Dobrzanski S, Duncan SE, Harkiss A, et al. Age and weight as determinants of warfarin requirements. J Clin Hosp Pharmacol 1983;8:75.
45. Steward DJ, Haining RL, Henna KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361.
46. Holm HA, Ly B, Handeland GF, Abidgaard U, et al. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16:30.
47. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): Results of a double-blind randomized study. Circulation 1989;80:935.
48. Bratt G, Aberg W, Johansson M, Tornebohm E, et al. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64:506.
49. Harenberg J, Huck K, Bratsch H, Stehle G, et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 1990;20(Suppl 1):205.
50. Siegbahn A, Y-Hassan S, Boberg J, Bylund A, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin: A dose finding study with LMWH-Novo. Thromb Res 1989;55:267.
51. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441.
52. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low-molecular-weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicentre trial. Thromb Haemost 1992; 68:14.
53. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541.
54. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost 1994;72:186.
55. Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Butler HR. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis, EASTERN Investigators. Thromb Haemost 2000;83:652.
56. Simonneau G, Sors H, Charbonier B, et al. A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337:663.
57. Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin versus heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000;160: 299.
58. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. Ann Intern Med 2004;140:175.
59. Koopman MMW, Prandoni P, Piovelia F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996;334:682.
60. Levine M, Gent M, Hirsh J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:667.
61. The Columbus Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657.
62. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low molecular weight heparin vs. intravenous heparin. An economic perspective. Arch Intern Med 1997;157:289.
63. Kakkar W, Gebska M, Kadziola Z, et al. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 2003;89:674.
64. van der Heijden JF, Hutten BA, Buller HR, et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2000;1:1.
65. Lee A, Levine M, Baker R, et al for the CLOT Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146.
66. Hull RD, Pineo GF, Mah AF, et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer. Thromb Haemost 2003;1(supplement July), abstract P137a.
67. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 2002;162(15):1729.
68. Levine MN, Planes A, Hirsh J, et al. The relationship between anti factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940.
69. Boneu B. Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994;72:330.
70. Rosenbloom D, Ginsberg JS. Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy. Can J Hosp Pharmacol 2002;55(1):15.
71. Nieuwenhuis HK, Albada J, Banga JD, et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2337.
72. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991;63:385.
73. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41(1):8.
74. Chow SL, Zammit K, West K, et al. Correlation of anti factor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003;43(6):586.
75. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002;143(5):753.
76. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special population. Pharmacotherapy 2001;21(2):218.
77. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225.
78. Mismetti P, Laporta-Simitsids S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998;79:1162.
79. Siguret V, Pautas E, Février WC, et al. Elderly patients treated with Tinzaparin (Innohep®) administered once daily (175 Anti-Xa IU/kg): Anti-Xa and Anti-IIa activities over 10 days. Thromb Haemost 2000;84(5):800.
80. Pautus E, Gouin I, Bellot O, et al. Safety profile of Tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Safety 2002;25(10):725.
81. Barrett JS, Gibiansky E, Hull RD, et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Intern J Clin Pharmacol Ther 2001;39(10):431.
82. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002;162:2605.
83. Andrassy K, Eschenfelder V. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 1996;81(Suppl. 2): S29.
84. Yee JYV, Duffull SB. The effect of body weight on dalteparin pharmacokinetics - A preliminary study. Eur J Clin Pharmacol 2000;56:293.
85. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001;31(1):42.
86. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with LMWH, tinzaparin: A pharmacodynamic study. Thromb Haemost 2002;87:817.
87. Barrett JS, Kernhauser DH, Hainer JW, et al. Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb Res 2001;101:243.
88. Kovacs MJ, Weir K, MacKinnon K, et al. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res 1998;91:137.
89. Planes A, Samama MM, Lensing AWA, et al. Prevention of deep vein thrombosis after hip replacement. Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:22.
90. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003;90:547.
91. Samama MM, Verhille C, Darchy L. Relation between weight, obesity and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery [abstract]). Thromb Haemost 1995;73(6):977.
92. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146(1):33.
93. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121(4):535.
94. Girolani B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: A prospective cohort study. Blood 2003;101(8): 2955.
95. Schmidt BP, Adelman B. Heparin-associated thrombocytopenia: A critical review and pooled analysis. Am J Med Sci 1993;305:208.
96. Warkentin TE, Levine MN, Hirsh J, Klama LN, Kelton JG. Formation of heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330.
97. Lundhoff-Last E, Nakov R, Misselwitz F, Breddin H-K, Bauersash R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol 2002;118:1137.
98. Ahmad S, Untch B, Haas S, Hoppensteadt DA, Misselwitz F, Messmore HL, Walenga JM, Fareed J. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with Clivarin and heparin: Implications in the HIT pathogenesis. Mol Cell Biochem 2004;258:163.
99. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003;121:786.
100. Dahlman TC. Osteoporotic fractures and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993;168:1265.
101. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002;87(2):182.
102. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002;87(2):182.
103. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71:7.
104. Shaughnessy SG, Hirsh J, Bhandari M, et al. Histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 1999;93:1231.
105. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997; 89:3236.
106. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002;116(1):178.
107. Dorffler-Melly J, de Jonge E, de Pont A-C, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002;359:849.